Chris Ryan

Chris Ryan joined OncLive in November 2021 as a senior editor and became the website's managing editor in October 2023. Before arriving at MJH Life Sciences, he spent nearly a decade covering professional and high school sports—including the New Jersey Devils and the NHL from 2016 to 2021—for The Star-Ledger and NJ.com. Email: chryan@onclive.com

Articles

Health Canada Approves Osimertinib for Locally Advanced, Unresectable EGFR+ NSCLC After Chemoradiation

May 22nd 2025

Osimertinib, with conditions, has been approved by Health Canada for locally advanced, unresectable NSCLC, harboring EGFR mutations.

FDA Grants Breakthrough Device Designation to EnVisio X1 for Minimally Invasive Surgery in Cancer Care

May 22nd 2025

The FDA granted breakthrough device designation to EnVisio X1 for minimally invasive surgery in cancer care.

Statin Use Is Not Associated With Improved Outcomes in Early HER2+ Breast Cancer

May 22nd 2025

A post hoc analysis from the APHINITY trial showed statin use did not improve survival in early-stage HER2-positive breast cancer.

FDA Votes Against Risk/Benefit Profile of Talazoparib Plus Enzalutamide for Non-HRR–Mutant mCRPC

May 21st 2025

The FDA’s ODAC voted 8 to 0 against the risk/benefit profile of talazoparib in combination with enzalutamide for patients with non-HRR–mutant mCRPC.

Dr Jain on Current Challenges in Defining Venetoclax Failure in CLL

May 21st 2025

Dr Zonder on the Importance of Personalized Medicine in Multiple Myeloma

May 21st 2025

Jeffrey Zonder, MD, discusses the importance of personalized medicine in the treatment of multiple myeloma.

Current Treatment Strategies in Pediatric R/R AML and ALL

May 21st 2025

Lia Gore, MD, and Sarah K. Tasian, MD, discuss current treatment trends in pediatric relapsed/refractory acute leukemia.

FDA’s ODAC Votes Against Risk/Benefit Profile of UGN-102 in Recurrent, Low-Grade, Intermediate-Risk NMIBC

May 21st 2025

The FDA’s ODAC voted against the risk/benefit profile of UGN-102 for recurrent, low-grade, intermediate-risk non–muscle-invasive bladder cancer.

FDA’s ODAC Votes in Favor of Risk/Benefit Profile of Subcutaneous Daratumumab for High-Risk Smoldering Myeloma

May 20th 2025

The FDA’s ODAC voted in favor of the risk/benefit profile of subcutaneous daratumumab in high-risk smoldering multiple myeloma.

Dr Fakih on the FDA Approval of Retifanlimab for Advanced Anal Cancer

May 20th 2025

Marwan Fakih, MD, discusses the clinical relevance of the FDA’s approval of retifanlimab for patients with squamous cell carcinoma of the anal canal.

Dr Falchi on the Safety of Fixed-Duration Epcoritamab Plus Lenalidomide/Rituximab in R/R Follicular Lymphoma

May 20th 2025

Lorenzo Falchi, MD, discusses the safety and pharmacodynamics of fixed-duration epcoritamab plus lenalidomide and rituximab in relapsed/refractory follicular lymphoma

The ‘Bar Is High’ to Usurp BCG, but Novel Therapies Could Drive Change in Bladder Cancer Management

May 20th 2025

Bogdana Schmidt, MD, MPH, discussed FDA-approved BCG-refractory treatments and recent shifts in BCG-naive NMIBC management.

Multidisciplinary Collaboration and Immunotherapy Help Overcome Treatment Challenges in MCC

May 20th 2025

Michael K. Wong, MD, PhD, FRCPC, discusses the landscape of Merkel cell carcinoma, including the role of immunotherapy and multidisciplinary treatment.

FDA ODAC Votes Against the Applicability of STARGLO Data for Glofitamab Plus Chemo for U.S. Patients With R/R DLBCL

May 20th 2025

The FDA’s ODAC voted against the applicability of STARGLO trial results to U.S. patients with relapsed/refractory DLBCL.

Experts Preview Key Presentations to Watch in Gynecologic Oncology at ASCO 2025

May 20th 2025

Experts highlight key abstracts and presentations to keep an eye on in gynecologic oncology at the 2025 ASCO Annual Meeting.

Dr LeVee on ADC Trials That May Inform the Evolution of Breast Cancer Management

May 19th 2025

Alexis LeVee, MD, discusses clinical trials investigating ADCs that may change treatment standards for patients with various subtypes of breast cancer.

postMONARCH ctDNA Analysis Underscores Benefit of Abemaciclib Plus Fulvestrant in HR+ Advanced Breast Cancer

May 19th 2025

An exploratory ctDNA analysis from postMONARCH highlighted the benefit of abemaciclib plus fulvestrant across HR-positive breast cancer subgroups.

FDA Grants Fast Track Designation to DLL3-Targeted ADC ZL-1310 in ES-SCLC

May 19th 2025

The DLL3-targeted antibody-drug conjugate ZL-1310 has received FDA fast track designation for patients with extensive-stage small cell lung cancer.

Belantamab Mafodotin–Based Combos Win Japanese Approval for R/R Myeloma

May 19th 2025

Two belantamab mafodotin–based combinations have been approved in Japan for relapsed/refractory multiple myeloma.

Tucatinib/Trastuzumab Yields Durable Responses in HER2-Mutated Metastatic Breast Cancer

May 19th 2025

Final analysis of SGNTUC-019 showed a 41.9% ORR, an 80.6% DCR, and a 18.2-month DOR with tucatinib/trastuzumab in pretreated, HER2-mutated metastatic breast cancer.